Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2014

Collaboration Agreement [Abstract]

Collaboration revenue with related party

The collaboration revenue the Company earned from Sanofi, as detailed below, consisted primarily of reimbursement for research and development expenses that the Company incurred in connection with the companies' antibody collaboration. In addition, Sanofi collaboration revenue for the three months and six months ended June 30, 2013 was reduced by two$10.0 million up-front payments to Sanofi in connection with the Company's acquisition from Sanofi of full exclusive rights to two families of novel antibodies, as described below.

	Three months ended June 30,
Sanofi Collaboration Revenue	2014			2013
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	$	(692	)	$	(8,216	)
Reimbursement of Regeneron research and development expenses	1,338			1,992
Other	1,484			2,227
Total ZALTRAP	2,130			(3,997		)
Antibody:
Reimbursement of Regeneron research and development expenses	137,893			105,274
Regeneron's share of commercialization expenses	(4,295		)	—
Up-front payments to Sanofi for acquisition of rights related to two antibodies	—			(20,000		)
Other	6,867			4,252
Total Antibody	140,465			89,526
Total Sanofi collaboration revenue	$	142,595		$	85,529

	Six months ended June 30,
Sanofi Collaboration Revenue	2014			2013
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	$	(3,904	)	$	(16,005	)
Reimbursement of Regeneron research and development expenses	2,430			4,081
Other	3,661			4,084
Total ZALTRAP	2,187			(7,840		)
Antibody:
Reimbursement of Regeneron research and development expenses	264,715			204,898
Regeneron's share of commercialization expenses	(4,295		)	—
Up-front payments to Sanofi for acquisition of rights related to two antibodies	—			(20,000		)
Other	10,496			7,744
Total Antibody	270,916			192,642
Total Sanofi collaboration revenue	$	273,103		$	184,802

Collaboration revenue

The collaboration revenue the Company earned from Bayer HealthCare is detailed below:

	Three months ended June 30,
Bayer HealthCare Collaboration Revenue	2014		2013
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	66,781	$	19,055
Sales milestones	15,000		—
Cost-sharing of Regeneron EYLEA development expenses	1,494		3,629
Other	10,813		8,420
Total EYLEA	94,088		31,104
PDGFR-beta antibody:
Cost-sharing of REGN2176-3 development expenses	626		—
Other	2,581		—
Total PDGFR-beta	3,207		—
Total Bayer HealthCare collaboration revenue	$	97,295	$	31,104

	Six months ended June 30,
Bayer HealthCare Collaboration Revenue	2014		2013
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	127,940	$	25,417
Sales milestones	45,000		—
Cost-sharing of Regeneron EYLEA development expenses	21,841		9,466
Other	21,745		11,128
Total EYLEA	216,526		46,011
PDGFR-beta antibody:
Cost-sharing of REGN2176-3 development expenses	1,139		—
Other	4,942		—
Total PDGFR-beta	6,081		—
Total Bayer HealthCare collaboration revenue	$	222,607	$	46,011